Diana Langworthy: New Episode – Solving the DOAC vs. Warfarin Mystery in Cirrhosis
Diana Langworthy, Associate Professor at University of Minnesota College of Pharmacy, shared a post on LinkedIn:
“New episode going live tomorrow, Tuesday June 30th, on What’s It Worth?
S4E7 – The Cirrhosis Paradox: Solving the DOAC vs. Warfarin Mystery in Liver Disease
Join me and my co-hosts, Dr. Erin E Pauling, (ambulatory care and cardiology specialist from Binghamton University) and recent U of MN grad, Dr. Caleb Nelson-Lange.
In this episode, we dig into a systematic review and meta-analysis comparing DOACs vs. warfarin in patients with atrial fibrillation and liver disease, including cirrhosis.
We talk through:
Why anticoagulation decisions in liver disease are so nuanced
What the evidence suggests about DOAC safety and effectiveness
How to think about agent selection, especially apixaban vs. rivaroxaban
Why observational data can be helpful, but still leaves important clinical gaps
And with this episode, there is a patient-facing companion episode:
S4E7.5 – AFib, Blood Thinners, and Liver Disease: Questions to Ask Your Doctor
This short What’s It Worth? For Everyone episode is designed for patients and families navigating AFib, blood thinners, liver disease, and cirrhosis.
It explains the topic in plain language and ends with practical questions patients can bring to their healthcare team.
For healthcare professionals: listen to the full episode for the evidence deep dive, and consider sharing the companion episode with patients or caregivers who want a clearer starting point for the conversation.”
Stay updated with Hemostasis Today.
-
Aug 16, 2026, 13:53Honey Blankenship: United by a Shared Commitment to the Bleeding Disorders Community
-
Aug 16, 2026, 13:46Sagar Bejalwar: A Rare Bleeding Disorder and the Importance of Specialized Care
-
Aug 16, 2026, 13:39Sharun Khan: Advancing Regenerative Medicine Through Veterinary Translational Science
-
Aug 16, 2026, 13:21Francois Roubille: New ESC Consensus on Inflammation in Coronary Syndromes
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?